Treatment exposure
At data cutoff, exposure to BAT1706 and EU‐bevacizumab was similar between the treatment arms. The median duration of therapy was 29.1 weeks (range: 3.0–62.1 weeks) in the BAT1706 arm and 27.0 weeks (range: 3.0–53.9 weeks) in the EU‐bevacizumab arm. Overall, patients in each treatment arm received a median of nine infusions of BAT1706 or EU‐bevacizumab. The median cumulative doses of BAT1706 and EU‐bevacizumab were 138.4 mg/kg and 130.1 mg/kg, respectively. Delays in BAT1706/EU‐bevacizumab dosing was reported in 161 patients in the BAT1706 arm (49.5%) and 155 patients the EU‐bevacizumab arm (47.8%), with the median dose delay being 7 days for both treatments.Median duration of exposure to carboplatin at data cutoff was similar between the two treatment arms: 17.9 weeks (range: 3.0–25.3 weeks) in the BAT1706 arm, and 17.7 weeks (range: 3.0–27.4 weeks) in the EU‐bevacizumab arm. Likewise, the median number of carboplatin infusions was similar: six in the BAT1706 arm, and five in the EU‐bevacizumab arm. The median cumulative carboplatin dose was 3264.6 mg in the BAT1706 arm and 2992.8 mg in the EU‐bevacizumab arm. Delays in carboplatin dosing were reported by 123 (37.8%) patients in the BAT1706 arm and 117 (36.1%) patients in the EU‐bevacizumab arm, with the median dose delay being 5 days in each arm. Carboplatin dose‐modification was reported in 51 (15.7%) and 56 (17.3%) patients in the BAT1706 and EU‐bevacizumab arms, respectively. Similar results to carboplatin were found for paclitaxel exposure. Overall, there were no differences between the treatment arms in exposure to carboplatin or paclitaxel across the study.